Article Sidebar

PDF
Date Published: 10/03/2021
Abstract Views: 344
Views PDF: 240
DOI: https://doi.org/10.51298/vmj.v498i1.26
Issue
Vol. 498 No. 1 (2021)
Section
Các bài báo
How to Cite
Duy Thông, V., & Ngọc Diễm, V. (2021). EFFECT OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC HEPATITIS B. Vietnam Medical Journal, 498(1). https://doi.org/10.51298/vmj.v498i1.26

EFFECT OF TENOFOVIR DISOPROXIL FUMARATE ON RENAL FUNCTION IN PATIENTS WITH CHRONIC HEPATITIS B

Võ Duy Thông1,, Võ Ngọc Diễm2
1 Bệnh viện Chợ Rẫy, Thành phố Hồ Chí Minh
2 Đại học Y Dược Thành phố Hồ Chí Minh

Main Article Content

Abstract

Objective: To evaluate the effect of tenofovir disoproxil fumarate (TDF) on renal function in patients with chronic hepatitis B. Methods: A cross-sectional study was conducted on 60 patients with chronic hepatitis B at University Medical Center HCMC from May 2017 to October 2020. Results: The mean age of patients was 42.10 ± 13.30; 39/60 (65%) of patients were male. The mean creatinine level significantly increased at 24th   and 48th week of treatment (p < 0.01), while eGFR level significantly decreased at 24th and 48th week (p<0.05). Conclusion: Renal function was decreased relative to baseline in chronic hepatitis B patients receiving TDF therapy, which indicates that the renal function should be monitored regularly in patients undergoing treatment with TDF.

Article Details

Keywords

TDF, renal function, chronic hepatitis B.

References

1. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis. 2013;37(7):944-950.
2. Goicoechea M, Liu S, Best B, Sun S, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102-108.
3. EASL clinical practice guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):67-185.
4. Pradat P, Le Pogam MA, Okon JB, Trolliet P, et al. Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate. J Viral Hepat. 2013; 20 (9): 650-657.
5. Koklu S, Gulsen M T, Tuna Y, Koklu H, et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther. 2015; 41 (3): 310-319.
6. Sarin SK, Kumar M, Lau GK, Abbas Z, et al (2016). Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10 (1): 1-98.
7. Jung WJ, Jang JY, Park WY, Jeong SW, et al. Effect of tenofovir on renal function in patients with chronic hepatitis B. Medicine (Baltimore). 2018; 97(7): e9756.
8. Vittal A, Ghany MG. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. Clin Liver Dis. 2019; 23(3): 417-432.